ArticleGastro hep advances2025
Adherence to Follow-Up Colonoscopy After a Positive Stool-Based Test in Patients Aged 45-49 Years: Real-World Differences Between Multitarget Stool DNA Testing and Fecal Immunochemical or Fecal Occult Blood Testing.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: A positive stool-based test (SBT) result requires timely follow-up colonoscopy (FU-CY) to realize the full benefits of screening recommendations. The current investigation examined the real-world rate of, and time to, FU-CY adherence among patients aged 45-49 years who were screened with either a fecal immunochemical test (FIT)/fecal occult blood test (FOBT) or a multitarget stool DNA test (mt-sDNA). Methods: This retrospective study utilized a large integrated national multipayer claims database. Patients were aged 45-49 years and had a positive SBT result between January 1, 2017, and June 30, 2022 (study period); the first screening test result served as the index date. The primary outcome was adherence to FU-CY, defined as evidence of a colonoscopy (based on Current Procedural Terminology codes) within 12 months of a positive SBT. Results: A total of 13,921 patients with a positive SBT result were identified during the study period (FIT/FOBT, n = 6429; mt-sDNA, n = 7492). Among those with a positive SBT, FU-CY adherence was significantly higher among patients screened with mt-sDNA compared to those with FIT/FOBT (85.0% vs 35.2%, respectively; Conclusion: FU-CY adherence rates were significantly higher in patients screened with mt-sDNA compared to those screened with FIT/FOBT. These results suggest that in younger patient populations, mt-sDNA may be a promising tool to improve FU-CY adherence rates and enhance the quality of colorectal cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.